Thiazolidinedione Safety and Efficacy in Ambulatory Patients Receiving Hemodialysis

Harold J. Manley, Pharm.D., Nicole M. Allcock, Pharm.D.


Pharmacotherapy. 2003;23(7) 

In This Article


The concern over increased intravascular volume and associated anemia, edema, and chronic heart failure in this patient population is not warranted. A possible reason for this is that any increase in intravascular volume will be removed by hemodialysis. We conclude that thiazolidinediones, specifically rosiglitazone and pioglitazone, are safe and effective for ambulatory patients receiving hemodialysis. However, we found that these drugs reduced systolic and diastolic blood pressure in these patients, which warrants further investigation.